CiRT	Checkpoint Inhibitor Response Test
CLIA	Clinical Laboratory Improvement Amendments
CPT PLA	Current Procedural Terminology Proprietary Laboratory Analyses Code
CR	Complete Response
CTLA-4	Cytotoxic T-Lymphocyte Antigen 4
ECOG	Eastern Cooperative Oncology Group
GCP	Good Clinical Practice
HEOR	Health Economic Outcomes Research
HPD	Hyperprogressive Disease
HPRR	High Probability of Response Result (CiRT classification)
ICI	Immune Checkpoint Inhibitor
IrAE	Immune-related Adverse Event
IRB	Institutional Review Board
LPRR	Low Probability of Response Result (CiRT classification)
MSI/MMR	Microsatellite Instability/Mismatch Repair
OS	Overall Survival
ORR	Objective Response Rate
PD	Progressive Disease
PD-1	Programmed Cell Death Protein 1
PD-L1	Programmed Death-Ligand 1
PFS	Progression-Free Survival
PR	Partial Response
RECIST	Response Evaluation Criteria in Solid Tumors
SD	Stable Disease
SDoH	Social Determinants of Health
TKI	Tyrosine Kinase Inhibitor
TMB	Tumor Mutational Burden
uHCC	Unresectable Hepatocellular Carcinoma (Advanced Liver Cancer)